Document 0086
 DOCN  M9470086
 TI    Alternating nevirapine and zidovudine treatment of human
       immunodeficiency virus type 1-infected persons does not prolong
       nevirapine activity.
 DT    9409
 AU    de Jong MD; Loewenthal M; Boucher CA; van der Ende I; Hall D; Schipper
       P; Imrie A; Weigel HM; Kauffmann RH; Koster R; et al; Department of
       Virology, Academic Medical Centre, University of; Amsterdam,
       Netherlands.
 SO    J Infect Dis. 1994 Jun;169(6):1346-50. Unique Identifier : AIDSLINE
       MED/94253598
 AB    The potential use of an alternating treatment strategy with nevirapine
       and zidovudine in prolonging the antiretroviral effects of nevirapine
       was evaluated. Ten human immunodeficiency virus type 1 (HIV-1)-infected
       p24 antigen-positive persons who had not received prior antiretroviral
       therapy were treated for 9-13 weeks with an alternating regimen of 1
       week of nevirapine (200 mg/day) and 3 weeks of zidovudine (600 mg/day).
       Serum p24 antigen levels declined during the first week of nevirapine
       treatment (median, 59%); however, subsequent courses of nevirapine were
       characterized by rising p24 antigen levels, while antigen levels
       remained stable or declined during zidovudine treatment. Serum beta
       2-microglobulin levels and CD4+ cell counts exhibited similar responses.
       HIV-1 isolates obtained from 2 patients revealed 40- and 1000-fold
       reductions in nevirapine sensitivity after 8 weeks. These findings
       demonstrate that alternating treatment with zidovudine and nevirapine
       does not prolong the effectiveness of nevirapine and does not prevent
       the development of nevirapine resistance.
 DE    Adolescence  Adult  Antiviral Agents/*THERAPEUTIC USE  Drug Resistance,
       Microbial  Drug Therapy, Combination  Human  HIV Core Protein p24/BLOOD
       HIV Infections/*DRUG THERAPY  HIV-1/*DRUG EFFECTS
       Pyridines/*THERAPEUTIC USE  Regression Analysis  Support, Non-U.S. Gov't
       Time Factors  Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).